Medical Device | January 25, 2022
Agilent announces the Innovative Seahorse XF Pro Analyzer
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
This surpasses the number of approvals supported in 2020
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Partnering to build biosynthesis processes and a pharmaceutical production platform
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Subscribe To Our Newsletter & Stay Updated
